Johnson & Johnson Cuts 56 Jobs Amid Shift from Spin-off to Full Sale of $20B Orthopedics Unit DePuy Synthes

This is the first round of layoffs Johnson & Johnson has carried out in the state this year. The previous layoff occurred in the fall of 2024, affecting 231 employees.

A Johnson & Johnson spokesperson responded in an email,This personnel adjustment is related to the spin-off plan for the orthopedics business within the company’s medical technology division.The plan was announced last October. A spokesperson stated,The company is continuing to advance the spin-off of its orthopedics business, addressing outstanding cost issues and identifying opportunities to improve operating margins to ensure sustained investment in patient-focused innovation.

Behind the recent headquarters layoffs, the divestiture path of Johnson & Johnson’s orthopedics business is showing a directional shift.

According to a Reuters report on February 20, 2026, Johnson & Johnson is reevaluating its plan to divest its orthopedics business, DePuy Synthes. Sources familiar with the matter revealed that the company is considering directly selling the division for over $20 billion, rather than proceeding with the previously planned spin-off into an independent publicly listed company.

Bloomberg was the first to report that Johnson & Johnson is exploring sale options. The report stated that large private equity firms are seen as the most likely acquirers, with some institutions already considering joint bids. It is also possible that competitors in the medical device industry may participate in the bidding for market consolidation purposes.

If the transaction closes at a $20 billion valuation, it will become one of the largest mergers and acquisitions in the medical device sector in recent years. Last year, DePuy Synthes generated approximately $9.2 billion in revenue, accounting for roughly one-tenth of Johnson & Johnson’s total revenue.

DePuy Synthes is not an organic entity but rather an empire cobbled together through two pivotal acquisitions.

In 1998, Johnson & Johnson acquired DePuy, Inc. for $3.5 billion, securing a leading position in the joint replacement market. In 2012, the company further acquired the Swiss firm Synthes for $21.3 billion, the largest transaction in its history at the time, thereby cementing its global dominance in trauma and spine care. Since then, Johnson & Johnson’s orthopedics division has evolved into a comprehensive platform spanning five key areas: joint reconstruction, spine, trauma, sports medicine, and surgical robotics. Among these, joint reconstruction is the largest profit contributor and holds the top global market share, while the trauma segment has long maintained its number-one position worldwide.

Such a multi-segment conglomerate, under the structure of a single listed company, is often priced as a whole. However, when facing private equity or strategic buyers, the value of each segment may be recalculated.Mature segments represented by joint reconstruction and trauma can provide stable cash flow; in recent years, the technological iterations and pricing pressures they face, along with those in fields such as spine and sports medicine, have manifested as distinct growth curves in financial reports;The spine and sports medicine sectors are characterized by rapid technological iteration and active emerging competitors; the Velys surgical robot represents a digital transformation that requires sustained R&D investment.

When assets with different attributes are combined, the aggregate valuation may not reflect the potential premium of each individual component. Once a sale process is initiated, buyers may be specifically attracted to the “flexibility value” inherent in the ability to divest, restructure, list separately, or resell these components individually.

03

Johnson & Johnson’s restructuring of its orthopedics business comes amid a broader trend of major medical device giants collectively “slimming down.” Zimmer Biomet sold its spine and dental businesses, Baxter divested its renal care division, and Medtronic and BD each disposed of their diabetes operations.

The common thread in these moves is not merely the divestiture of loss-making assets. The assets being sold are often mature leaders in their respective fields. By realizing value at this juncture, these giants can redeploy the substantial capital recovered into high-growth, frontier sectors that require sustained capital investment.Johnson & Johnson’s pharmaceutical segment continues to expand in key therapeutic areas such as oncology and immunology. Within its MedTech segment, businesses like surgical robotics and electrophysiology require significantly higher capital investment than traditional implants. In this context, the $20 billion inflow from the sale of its orthopedics business will not only reshape the company’s balance sheet but also redefine the direction and intensity of its investments over the next decade.

Based on currently available public information, Johnson & Johnson is not expected to disclose any further material developments regarding the transaction before mid-2026. Attention will remain focused on the potential buyer list for DePuy Synthes, the final deal structure, and the subsequent impact on the global orthopedic competitive landscape.